|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-7-29
|
|
pubmed:abstractText |
Pancreatitis is the most common complication of ERCP. Calcium channel inhibitors have been shown to prevent the development of experimental pancreatitis. The aim of this randomized, placebo-controlled trial was to determine whether the calcium channel blocker nifedipine prevents post-ERCP pancreatitis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0016-5107
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
202-8
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12145597-Acute Disease,
pubmed-meshheading:12145597-Adult,
pubmed-meshheading:12145597-Aged,
pubmed-meshheading:12145597-Aged, 80 and over,
pubmed-meshheading:12145597-Calcium Channel Blockers,
pubmed-meshheading:12145597-Cholangiopancreatography, Endoscopic Retrograde,
pubmed-meshheading:12145597-Female,
pubmed-meshheading:12145597-Humans,
pubmed-meshheading:12145597-Male,
pubmed-meshheading:12145597-Middle Aged,
pubmed-meshheading:12145597-Nifedipine,
pubmed-meshheading:12145597-Pain, Postoperative,
pubmed-meshheading:12145597-Pancreatitis,
pubmed-meshheading:12145597-Prospective Studies,
pubmed-meshheading:12145597-Risk Factors,
pubmed-meshheading:12145597-Sphincterotomy, Endoscopic
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study.
|
|
pubmed:affiliation |
Service des Maladies du Foie et de l'Appareil Digestif, CHU de Bicêtre, Le Kremlin-Bicêtre, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
